EW Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

1.54B

+11.22%

0.619

+4.94%

1.57B

+10.89%

0.679

+6.02%

1.67B

+9.08%

0.724

+8.1%

Estimates Revision

The market is revising Upward the revenue expectations for Edwards Lifesciences Corporation (EW) for FY2025, with the revenue forecasts being adjusted by 1.02% over the past three months. During the same period, the stock price has changed by 9.64%.

Revenue Estimates for FY2025

Revise Upward

+1.02%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+3.24%

In Past 3 Month

Stock Price

Go Up

+9.64%

In Past 3 Month

24 Analyst Rating

Wall Street analysts forecast EW stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for EW is 92.95 USD with a low forecast of 83.00 USD and a high forecast of 104.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

14 Buy

10 Hold

0 Sell

Moderate Buy

Current: 83.380

Low

83.00

Averages

92.95

High

104.00

Current: 83.380

Low

83.00

Averages

92.95

High

104.00

Citi

Joanne Wuensch

maintain

$96 -> $101

2025-12-11

New

Reason

Citi

Joanne Wuensch

Price Target

$96 -> $101

2025-12-11

New

maintain

Reason

Citi analyst Joanne Wuensch raised the firm's price target on Edwards Lifesciences to $101 from $96 and keeps a Buy rating on the shares. The firm adjusted ratings and targets in the medical technology sector as part of its 2026 outlook. The group is "bouncing off its lows," and there is further upside potential in 2026, the analyst tells investors in a research note. Citi believes the S&P Equipment and Supplies index "remains undervalued and underappreciated." The firm expects a rebound next year due to company catalysts and sector rotation.

Barclays

Overweight

maintain

$99 -> $103

2025-12-08

Reason

Barclays

Price Target

$99 -> $103

2025-12-08

maintain

Overweight

Reason

Barclays raised the firm's price target on Edwards Lifesciences to $103 from $99 and keeps an Overweight rating on the shares. The firm says the company's pipeline update and long-term plan reinforce its "commitment to growth, innovation and therapeutic development." The analyst sees Edwards' clinical- and pipeline-related catalysts to continue to drive durable growth and shareholder returns.

Stifel

Buy

maintain

$95 -> $100

2025-12-05

Reason

Stifel

Price Target

$95 -> $100

2025-12-05

maintain

Buy

Reason

Stifel raised the firm's price target on Edwards Lifesciences to $100 from $95 and keeps a Buy rating on the shares after having attended Edwards' annual investor day meeting. The firm, which says initial 2026 guidance "looks like a solid starting point," left the meeting feeling positive about Edwards' 2026 outlook and long-term set-up, the analyst tells investors.

Baird

David Rescott

Neutral

maintain

$83 -> $88

2025-12-05

Reason

Baird

David Rescott

Price Target

$83 -> $88

2025-12-05

maintain

Neutral

Reason

Baird analyst David Rescott raised the firm's price target on Edwards Lifesciences to $88 from $83 and keeps a Neutral rating on the shares. The firm updated its model following its Investor Day which painted an improving story while noting there appears to be few catalysts until 2027.

UBS

Neutral

maintain

$90 -> $92

2025-12-05

Reason

UBS

Price Target

$90 -> $92

2025-12-05

maintain

Neutral

Reason

UBS raised the firm's price target on Edwards Lifesciences to $92 from $90 and keeps a Neutral rating on the shares following the analyst day. The firm says the company's long-term guidance could prove conservative.

Truist

Hold

maintain

$90 -> $92

2025-12-05

Reason

Truist

Price Target

$90 -> $92

2025-12-05

maintain

Hold

Reason

Truist raised the firm's price target on Edwards Lifesciences to $92 from $90 and keeps a Hold rating on the shares. The company's Investor Day set a reasonable and highly achievable outlook that essentially bracketed consensus on all metrics, the analyst tells investors in a research note. With TAVR growth re-accelerating in Q3, and catalysts across TAVR and TMTT into 2026-2027, the narrative is certainly on the side of the company heading into the new year, Truist added.

Valuation Metrics

The current forward P/E ratio for Edwards Lifesciences Corp (EW.N) is 30.18, compared to its 5-year average forward P/E of 34.76. For a more detailed relative valuation and DCF analysis to assess Edwards Lifesciences Corp 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

5Y Average PE

34.76

Current PE

30.18

Overvalued PE

41.71

Undervalued PE

27.81

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

5Y Average EV/EBITDA

27.26

Current EV/EBITDA

22.99

Overvalued EV/EBITDA

32.89

Undervalued EV/EBITDA

21.63

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

9.14

Current PS

7.46

Overvalued PS

11.27

Undervalued PS

7.00

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

N/A

ROIC

Trading Trends

Insider

Insiders areSelling! The selling amount has increased 226.77% over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress areSelling! The selling amount has increased368.75%over the last month.

Sold

Bought

Insider

Insiders areSelling! The selling amount has increased 226.77% over the last month.

Sold

Bought

EW News & Events

Events Timeline

No data

News

4.0

12-05Benzinga

Broadcom Set to Surge Over 14%? Check Out 10 Leading Analyst Predictions for Friday

7.0

11-30PRnewswire

Halper Sadeh Investigates Edwards Lifesciences for Potential Fiduciary Breaches

9.5

11-28NASDAQ.COM

Edwards Lifesciences (EW) Earnings Call Transcript

People Also Watch

Frequently Asked Questions

What is Edwards Lifesciences Corp (EW) stock price today?

The current price of EW is 83.38 USD — it has increased 0.36 % in the last trading day.

What is Edwards Lifesciences Corp (EW)'s business?

Edwards Lifesciences Corporation is the global structural heart company. The Company partners with clinicians and researchers and invests in research and development to improve care for those impacted by structural heart disease. Its product categories include Transcatheter Aortic Valve Replacement (TAVR), Transcatheter Mitral and Tricuspid Therapies (TMTT), and Surgical Structural Heart. It provides transcatheter heart valve replacement technologies designed for the minimally-invasive replacement of aortic heart valves. TAVR category includes the Edwards SAPIEN 3, the Edwards SAPIEN 3 Ultra and the Edwards SAPIEN 3 Ultra RESILIA systems. TMTT category includes the PASCAL Precision transcatheter repair system, EVOQUE tricuspid valve replacement system and Cardioband tricuspid valve reconstruction system. Its INSPIRIS RESILIA aortic valve, offers RESILIA tissue and VFit technology. It is managed in various geographical regions, such as United States, Europe, Japan and Rest of World.

What is the price predicton of EW Stock?

What is Edwards Lifesciences Corp (EW)'s revenue for the last quarter?

Edwards Lifesciences Corp revenue for the last quarter amounts to 1.55B USD, increased 14.67 % YoY.

What is Edwards Lifesciences Corp (EW)'s earnings per share (EPS) for the last quarter?

Edwards Lifesciences Corp. EPS for the last quarter amounts to 0.50 USD, decreased -90.25 % YoY.

What changes have occurred in the market's expectations for Edwards Lifesciences Corp (EW)'s fundamentals?

How many employees does Edwards Lifesciences Corp (EW). have?

Edwards Lifesciences Corp (EW) has 15800 emplpoyees as of December 15 2025.

What is Edwards Lifesciences Corp (EW) market cap?

Today EW has the market capitalization of 48.21B USD.